You are here: Industry Insights > ADHD

News List

Akili's video game digital treatment shows promise in ADHD, eyes FDA approval pharmafile
December 05, 2017
Akili, an unlisted affiliate of London-listed PureTech Health, has unveiled top-line results of AKL-T01, a novel digital medicine which takes the form of a video game, in the treatment of paediatric attention deficit hyperactivity disorder (ADHD).
UK children experiencing chronic delays in ADHD diagnosis pharmatimes
November 06, 2017
Young people in the UK with ADHD are at “serious risk of social and mental health harm” because they experience some of the “longest and most complicated” delays to diagnosis anywhere in Europe, a group of experts is warning.
Shire’s Intuniv hits targets in adult ADHD trial pharmatimes
September 21, 2017
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient group.
FDA approves Mydayis – a once-daily option for ADHD symptom control in patients 13 years plus cphi-online
June 27, 2017
Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared with placebo, in total score on a skill-adjusted math test that measures attention in ADHD.
Shire secures US nod for once-daily ADHD drug pharmatimes
June 23, 2017
Shire has finally bagged approval in the US for its long-acting attention deficit hyperactivity disorder drug (ADHD) Mydayis.
NLS Pharma Unveils Positive Phase 2 Data For NLS-1 (mazindol CR) In Adults With ADHD, Demonstrating en-cphi.cn
June 01, 2017
NLS-1 (mazindol CR) is not a stimulant, yet yields large effect size of 1.09 (using the ADHD-RS-DSM-5 scale)
FDA approves first generic Strattera for the treatment of ADHD europeanpharmaceuticalreview
June 01, 2017
The US Food and Drug Administration (FDA) has approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Otsuka to acquire Neurovance in potential $250 million deal pharmafile
March 07, 2017
Otsuka Pharmaceuticals, a pharmaceutical firm with headquarters in Japan, has agreed to pay...
Alcobra halts development of metadoxine for ADHD after failed Phase III trial; shares plunge firstwordpharma
January 18, 2017
Alcobra announced Tuesday that it was terminating the development of its experimental extended-release formulation of metadoxine for adults with attention deficit-hyperactivity disorder (ADHD)...
Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024 pharmaasia
January 16, 2017
ADHD market to reach $13.9 billion by 2024 in US, the EU, and Japan, as awareness increases and drugs improve.

Previous page 1 2 3 4 5 6 Next page